- Diagnostic Différentiel
Drug Information for Simulect (Novartis Pharmaceuticals Corporation): OVERDOSAGE
- CLINICAL STUDIES
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- Diseases/Conditions Related to Simulect (Novartis Pharmaceuticals Corporation)
- Liens externes liés à Simulect (Novartis Pharmaceuticals Corporation)
A maximum tolerated dose of Simulect® (basiliximab) has not been determined in patients. During the course of clinical studies, Simulect has been administered to adult renal transplantation patients in single doses of up to 60 mg, or in divided doses over 3-5 days of up to 120 mg, without any associated serious adverse events. There has been one spontaneous report of a pediatric renal transplantation patient who received a single 20-mg dose (2.3 mg/kg) without adverse events.
- Drug Information Provided by National Library of Medicine (NLM).